OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)
John J.V. McMurray, David L. DeMets, Silvio E. Inzucchi, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 5, pp. 665-675
Open Access | Times Cited: 370
John J.V. McMurray, David L. DeMets, Silvio E. Inzucchi, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 5, pp. 665-675
Open Access | Times Cited: 370
Showing 1-25 of 370 citing articles:
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J.V. McMurray, Scott D. Solomon, Silvio E. Inzucchi, et al.
New England Journal of Medicine (2019) Vol. 381, Iss. 21, pp. 1995-2008
Open Access | Times Cited: 5281
John J.V. McMurray, Scott D. Solomon, Silvio E. Inzucchi, et al.
New England Journal of Medicine (2019) Vol. 381, Iss. 21, pp. 1995-2008
Open Access | Times Cited: 5281
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
Mark C. Petrie, Subodh Verma, Kieran F. Docherty, et al.
JAMA (2020) Vol. 323, Iss. 14, pp. 1353-1353
Open Access | Times Cited: 437
Mark C. Petrie, Subodh Verma, Kieran F. Docherty, et al.
JAMA (2020) Vol. 323, Iss. 14, pp. 1353-1353
Open Access | Times Cited: 437
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction
Michael E. Nassif, Sheryl L. Windsor, Fengming Tang, et al.
Circulation (2019) Vol. 140, Iss. 18, pp. 1463-1476
Open Access | Times Cited: 355
Michael E. Nassif, Sheryl L. Windsor, Fengming Tang, et al.
Circulation (2019) Vol. 140, Iss. 18, pp. 1463-1476
Open Access | Times Cited: 355
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction
Mikhail Kosiborod, Pardeep S. Jhund, Kieran F. Docherty, et al.
Circulation (2019) Vol. 141, Iss. 2, pp. 90-99
Open Access | Times Cited: 297
Mikhail Kosiborod, Pardeep S. Jhund, Kieran F. Docherty, et al.
Circulation (2019) Vol. 141, Iss. 2, pp. 90-99
Open Access | Times Cited: 297
Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
Milton Packer, Javed Butler, Gerasimos Filippatos, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 10, pp. 1270-1278
Open Access | Times Cited: 249
Milton Packer, Javed Butler, Gerasimos Filippatos, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 10, pp. 1270-1278
Open Access | Times Cited: 249
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction
Pardeep S. Jhund, Scott D. Solomon, Kieran F. Docherty, et al.
Circulation (2020) Vol. 143, Iss. 4, pp. 298-309
Open Access | Times Cited: 239
Pardeep S. Jhund, Scott D. Solomon, Kieran F. Docherty, et al.
Circulation (2020) Vol. 143, Iss. 4, pp. 298-309
Open Access | Times Cited: 239
Highlights in heart failure
Daniela Tomasoni, Marianna Adamo, Carlo Lombardi, et al.
ESC Heart Failure (2019) Vol. 6, Iss. 6, pp. 1105-1127
Open Access | Times Cited: 212
Daniela Tomasoni, Marianna Adamo, Carlo Lombardi, et al.
ESC Heart Failure (2019) Vol. 6, Iss. 6, pp. 1105-1127
Open Access | Times Cited: 212
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
Pardeep S. Jhund, Toru Kondo, Jawad H. Butt, et al.
Nature Medicine (2022) Vol. 28, Iss. 9, pp. 1956-1964
Open Access | Times Cited: 200
Pardeep S. Jhund, Toru Kondo, Jawad H. Butt, et al.
Nature Medicine (2022) Vol. 28, Iss. 9, pp. 1956-1964
Open Access | Times Cited: 200
Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy
Anja Schork, Janine Saynisch, Andreas Vosseler, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 189
Anja Schork, Janine Saynisch, Andreas Vosseler, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 189
The Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA‐HF) trial: baseline characteristics
John J.V. McMurray, David L. DeMets, Silvio E. Inzucchi, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 11, pp. 1402-1411
Open Access | Times Cited: 188
John J.V. McMurray, David L. DeMets, Silvio E. Inzucchi, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 11, pp. 1402-1411
Open Access | Times Cited: 188
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age
Felipe A. Martínez, Matteo Serenelli, José Carlos Nicolau, et al.
Circulation (2019) Vol. 141, Iss. 2, pp. 100-111
Open Access | Times Cited: 179
Felipe A. Martínez, Matteo Serenelli, José Carlos Nicolau, et al.
Circulation (2019) Vol. 141, Iss. 2, pp. 100-111
Open Access | Times Cited: 179
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
James P. Curtain, Kieran F. Docherty, Pardeep S. Jhund, et al.
European Heart Journal (2021) Vol. 42, Iss. 36, pp. 3727-3738
Open Access | Times Cited: 176
James P. Curtain, Kieran F. Docherty, Pardeep S. Jhund, et al.
European Heart Journal (2021) Vol. 42, Iss. 36, pp. 3727-3738
Open Access | Times Cited: 176
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
Kieran F. Docherty, Pardeep S. Jhund, Silvio E. Inzucchi, et al.
European Heart Journal (2020) Vol. 41, Iss. 25, pp. 2379-2392
Open Access | Times Cited: 171
Kieran F. Docherty, Pardeep S. Jhund, Silvio E. Inzucchi, et al.
European Heart Journal (2020) Vol. 41, Iss. 25, pp. 2379-2392
Open Access | Times Cited: 171
The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction
Coenraad Withaar, Laura M G Meems, George Markousis‐Mavrogenis, et al.
Cardiovascular Research (2020) Vol. 117, Iss. 9, pp. 2108-2124
Open Access | Times Cited: 157
Coenraad Withaar, Laura M G Meems, George Markousis‐Mavrogenis, et al.
Cardiovascular Research (2020) Vol. 117, Iss. 9, pp. 2108-2124
Open Access | Times Cited: 157
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction
David D. Berg, Pardeep S. Jhund, Kieran F. Docherty, et al.
JAMA Cardiology (2021) Vol. 6, Iss. 5, pp. 499-499
Open Access | Times Cited: 156
David D. Berg, Pardeep S. Jhund, Kieran F. Docherty, et al.
JAMA Cardiology (2021) Vol. 6, Iss. 5, pp. 499-499
Open Access | Times Cited: 156
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure
Petar Seferović, Andrew J.S. Coats, Piotr Ponikowski, et al.
European Journal of Heart Failure (2019) Vol. 22, Iss. 2, pp. 196-213
Open Access | Times Cited: 155
Petar Seferović, Andrew J.S. Coats, Piotr Ponikowski, et al.
European Journal of Heart Failure (2019) Vol. 22, Iss. 2, pp. 196-213
Open Access | Times Cited: 155
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
Alice M. Jackson, Pooja Dewan, Inder S. Anand, et al.
Circulation (2020) Vol. 142, Iss. 11, pp. 1040-1054
Open Access | Times Cited: 155
Alice M. Jackson, Pooja Dewan, Inder S. Anand, et al.
Circulation (2020) Vol. 142, Iss. 11, pp. 1040-1054
Open Access | Times Cited: 155
Empagliflozin protects heart from inflammation and energy depletion via AMPK activation
Chintan N. Koyani, Ioanna Plastira, Harald Sourij, et al.
Pharmacological Research (2020) Vol. 158, pp. 104870-104870
Closed Access | Times Cited: 146
Chintan N. Koyani, Ioanna Plastira, Harald Sourij, et al.
Pharmacological Research (2020) Vol. 158, pp. 104870-104870
Closed Access | Times Cited: 146
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction
Jawad H. Butt, Pooja Dewan, Béla Merkely, et al.
Annals of Internal Medicine (2022) Vol. 175, Iss. 6, pp. 820-830
Closed Access | Times Cited: 101
Jawad H. Butt, Pooja Dewan, Béla Merkely, et al.
Annals of Internal Medicine (2022) Vol. 175, Iss. 6, pp. 820-830
Closed Access | Times Cited: 101
Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology
Marco Metra, Daniela Tomasoni, Marianna Adamo, et al.
European Journal of Heart Failure (2023) Vol. 25, Iss. 6, pp. 776-791
Open Access | Times Cited: 98
Marco Metra, Daniela Tomasoni, Marianna Adamo, et al.
European Journal of Heart Failure (2023) Vol. 25, Iss. 6, pp. 776-791
Open Access | Times Cited: 98
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF
Carly Adamson, Kieran F. Docherty, Hiddo J.L. Heerspink, et al.
Circulation (2022) Vol. 146, Iss. 6, pp. 438-449
Open Access | Times Cited: 93
Carly Adamson, Kieran F. Docherty, Hiddo J.L. Heerspink, et al.
Circulation (2022) Vol. 146, Iss. 6, pp. 438-449
Open Access | Times Cited: 93
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
Kieran F. Docherty, Paul Welsh, Subodh Verma, et al.
Circulation (2022) Vol. 146, Iss. 13, pp. 980-994
Open Access | Times Cited: 93
Kieran F. Docherty, Paul Welsh, Subodh Verma, et al.
Circulation (2022) Vol. 146, Iss. 13, pp. 980-994
Open Access | Times Cited: 93
Pharmacotherapy of type 2 diabetes: An update and future directions
Antea DeMarsilis, Niyoti Reddy, Chrysoula Boutari, et al.
Metabolism (2022) Vol. 137, pp. 155332-155332
Closed Access | Times Cited: 93
Antea DeMarsilis, Niyoti Reddy, Chrysoula Boutari, et al.
Metabolism (2022) Vol. 137, pp. 155332-155332
Closed Access | Times Cited: 93
Deranged Myocardial Fatty Acid Metabolism in Heart Failure
Tsunehisa Yamamoto, Motoaki Sano
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 996-996
Open Access | Times Cited: 69
Tsunehisa Yamamoto, Motoaki Sano
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 996-996
Open Access | Times Cited: 69
Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan
Scott D. Solomon, Pardeep S. Jhund, Brian Claggett, et al.
JACC Heart Failure (2020) Vol. 8, Iss. 10, pp. 811-818
Open Access | Times Cited: 118
Scott D. Solomon, Pardeep S. Jhund, Brian Claggett, et al.
JACC Heart Failure (2020) Vol. 8, Iss. 10, pp. 811-818
Open Access | Times Cited: 118
